Evaluation of the Possibility to Delegate Glaucoma Surveillance to Orthoptists in Hospital

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02876185

Acronym

GLAUS

Enrollment

133

Registered

2016-08-23

Start date

2016-04-08

Completion date

2023-05-05

Last updated

2024-10-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Glaucoma

Keywords

Glaucoma surveillance, Orthoptist

Brief summary

Glaucoma is a progressive optical neuropathy, generally associated with ocular hypertension. The treatment aims to stabilize the visual field deficiencies by lowering the intraocular pressure. Due to the fluctuation of the visual field test and re-test measures, the European recommendations are to obtain 6 visual field tests in 2 years (or one every 4 months) in order to know if the pathology is progressing despite the current treatment (or if the treatment is necessary, in cases of intraocular hypertensions). The lack of ophthalmologists renders the monitoring of a beginning glaucoma, rarely compatible with the present recommendations. It is therefore crucial to evaluate new therapeutic alternatives, when faced to a decreasing medical demography and an increase the patient's needs. This study should allow to validate the possibility to delegate monitoring tasks to orthoptists during glaucoma surveillance. To organize the delegation of this surveillance to orthoptists would permit a better distribution of the ophthalmologist's activities.

Interventions

OTHERMonitoring by an orthoptist then by an ophthalmologist

At each visit, the usual monitoring tests will be collected and viewed by the orthoptist then by the ophthalmologist concerning the necessity of an anticipated ophthalmological consultation

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Age from 18 years old or more * Open-angle glaucoma or ocular hypertension

Exclusion criteria

* Other active ocular pathology * Monophthalmic patients * Patients requiring a Goldmann visual field exam * Opposition of the patient to participate to the trial * Pregnant women or breastfeeding * Patient under juridical protection * Lack of affiliation to social security or universal health coverage

Design outcomes

Primary

Measure	Time frame
detection by the orthoptists of an abnormality that would require an anticipated ophthalmologic consultation	20 month of follow-up

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026